4.7 Meeting Abstract

Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT plus TMZ vs RT plus nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 34, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2016.34.15_suppl.2016

Keywords

-

Categories

Funding

  1. NCI [U10CA21661, U10CA180868, U10CA180822, U10CA37422, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01]
  2. Bristol Myers Squibb
  3. Merck Co.
  4. Brain Tumor Funders Collaborative Grant
  5. Ohio State University CCC

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available